HM 95573Alternative Names: HM95573
Latest Information Update: 03 Oct 2016
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours